| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 12/19/2001 | EP1163334A1 Polynucleotide and deduced amino acid sequences from stromal cells |
| 12/19/2001 | EP1163332A1 48 human secreted proteins |
| 12/19/2001 | EP1163331A1 50 human secreted proteins |
| 12/19/2001 | EP1163267A1 47 human secreted proteins |
| 12/19/2001 | EP1163255A1 50 human secreted proteins |
| 12/19/2001 | EP1163254A2 Trpm-2 antisense therapy |
| 12/19/2001 | EP1163253A2 Syndesmos and uses thereof |
| 12/19/2001 | EP1163252A2 Compositions, kits, and methods relating to the human fez1 gene, a novel tumor suppressor gene |
| 12/19/2001 | EP1163024A1 Delivery of macromolecules into cells |
| 12/19/2001 | EP1162993A2 Use of casb616 polypeptides and polynucleotides for cancer treatment |
| 12/19/2001 | EP1162955A1 Nanoparticles, complexes with polynucleotides and their use |
| 12/19/2001 | EP1162915A1 Electromagnetic object detector provided with an additional electrode and intended for a medical radiation apparatus |
| 12/19/2001 | EP1162884A1 Oral low dose butyrate compositions |
| 12/19/2001 | EP0979093B1 Arrestable therapeutic viral agent |
| 12/19/2001 | EP0941318B9 Dumbbell expression constructs for gene therapy |
| 12/19/2001 | EP0758387B1 Thymidine kinase mutants |
| 12/19/2001 | EP0746624B1 Vector for liver-specific gene expression |
| 12/19/2001 | CN1327452A Fibroblast growth factor with hepatocyte proliferation activity |
| 12/19/2001 | CN1327449A Human cervical cancer 1 protooncogene and protein encoded therein |
| 12/19/2001 | CN1327388A Modified antibodies of induced anti-idiotype reaction enhancement |
| 12/19/2001 | CN1326990A New polypeptide-human DNA-like CGG repeative conjugated protein 16.17 and polynucleotide for encoding such polypeptide |
| 12/19/2001 | CN1326982A New polypeptide-pogo transposon 18 and polynucleotide for encoding such polypeptide |
| 12/19/2001 | CN1326938A Antigene V-erb B oligonucleotide and its use |
| 12/18/2001 | US6331615 Nucleic acid molecule encoding heavy or light chain of an antibody which specifically recognizes a protein specifically recognized by monoclonal antibody 5c8 (anti-CD40 ligand) |
| 12/18/2001 | US6331613 Nucleotide sequences coding protein associated with cytokine activity; for use in treating allergies, autoimmune diseases and acquired immune deficiency syndrome; for preventing cell differentiation; for activating tissue regeneration |
| 12/18/2001 | US6331527 Promoter smooth muscle cell expression |
| 12/18/2001 | US6331526 Method of inhibiting the proliferation and causing the differentiation of cells with IGF-1 receptor antisense oligonucleotides |
| 12/18/2001 | US6331525 Targeted delivery of genes encoding interferon |
| 12/18/2001 | US6331524 Organ-specific targeting of cationic amphiphile / DNA complexes for gene therapy |
| 12/18/2001 | US6331433 Human T cell leukemia cell line designated D1.1 |
| 12/18/2001 | US6331417 Determine amount of target nucleotide sequences in sample; mix sample with control sequences, incubate with nucleotide sequences, perform nucleotide sequence amplification, calculate amount of control and target sequences |
| 12/18/2001 | US6331411 TopA |
| 12/18/2001 | US6331410 Polynucleotides encoding a novel pyrR homolog |
| 12/18/2001 | US6331406 Human enbryonic germ cell and methods of use |
| 12/18/2001 | US6331394 Contacting candidate mixture of nucleic acids with integrin, wherein nucleic acids having increased affinity to integrin relative to candidate mixture may be partitioned from remainder of mixture, partitioning, amplififying |
| 12/18/2001 | US6331299 Method for treatment of cancer and infectious disease and compositions useful in same |
| 12/18/2001 | US6331284 P202 is a tumor suppressor |
| 12/18/2001 | CA2221448C Antisense oligonucleotide modulation of raf gene expression |
| 12/13/2001 | WO2001094636A2 Compositions, kits, and methods for identification and modulation of type i diabetes |
| 12/13/2001 | WO2001094631A1 Methods for detection of cryptosporidium species and isolates and for diagnosis of cryptosporidiuminfections |
| 12/13/2001 | WO2001094613A2 Methods and compounds for influencing beta3 integrin-dependent intracellular processes |
| 12/13/2001 | WO2001094610A2 Binary hybrid mutational vectors |
| 12/13/2001 | WO2001094605A2 Recombinant aav vectors for gene therapy of obesity |
| 12/13/2001 | WO2001094586A2 Non-agonistic antibodies to human gp39, compositions containing, and therapeutic use thereof |
| 12/13/2001 | WO2001094570A2 Transfection method |
| 12/13/2001 | WO2001094560A2 In vitro assembly of sv40 viruses and pseudoviruses |
| 12/13/2001 | WO2001094557A1 Human chemokine beta-10 mutant polypeptides |
| 12/13/2001 | WO2001094555A1 Method for obtaining characterised muscle-derived cell populations and uses |
| 12/13/2001 | WO2001094551A2 Genetically modified t-cells, method for producing them and use thereof |
| 12/13/2001 | WO2001094420A1 Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury |
| 12/13/2001 | WO2001094413A2 B7-related nucleic acids and polypeptides and their uses for immunomodulation |
| 12/13/2001 | WO2001094400A2 A GENE ENCODING A MULTIDRUG RESISTANCE HUMAN P-GLYCOPROTEIN HOMOLOGUE ON CHROMOSOME 7p15-21 AND USES THEREOF |
| 12/13/2001 | WO2001094391A2 Intracellular signaling proteins |
| 12/13/2001 | WO2001094387A2 Epididymis-specific proteins with fibronectin type ii modules |
| 12/13/2001 | WO2001094383A2 Mutated furin polypeptides having improved characteristics |
| 12/13/2001 | WO2001093914A2 Multivalent platform molecules comprising high molecular weight polyethylene oxide |
| 12/13/2001 | WO2001093902A2 Immunostimulatory rna/dna hybrid molecules |
| 12/13/2001 | WO2001093901A1 Combined preparation for the treatment of neoplasic diseases |
| 12/13/2001 | WO2001093885A1 Therapeutic agents - ii |
| 12/13/2001 | WO2001093884A1 Therapeutic agents - i |
| 12/13/2001 | WO2001093883A1 Therapeutic agents - iii |
| 12/13/2001 | WO2001093836A2 Encapsulation of polynucleotides and drugs into targeted liposomes |
| 12/13/2001 | WO2001093835A1 Delivery systems for bioactive agents |
| 12/13/2001 | WO2001070968A3 Production of recombinant blood clotting factors in human cell lines |
| 12/13/2001 | WO2001068147A3 Synthetic oligonucleotides as inducers of erythroid differentiation |
| 12/13/2001 | WO2001055325A8 Nucleic acids, proteins, and antibodies |
| 12/13/2001 | WO2001055206A8 Nucleic acids, proteins, and antibodies |
| 12/13/2001 | WO2001055205A8 Nucleic acids, proteins, and antibodies |
| 12/13/2001 | WO2001046408A3 Molecular clones with mutated hiv gag/pol, siv gag and siv env genes |
| 12/13/2001 | WO2001045735A3 Compositions and vaccines containing antigen(s) of cryptosporidium parvum and of another enteric pathogen |
| 12/13/2001 | WO2001044445A3 Human lyases and associated proteins |
| 12/13/2001 | WO2001042424A3 Sphingolipid-containing cationic liposomes for topical delivery of bioactive material |
| 12/13/2001 | WO2001037881A3 Gene therapy of hiv-positive patients by the expression of membrane-anchored gp41 peptides |
| 12/13/2001 | WO2001032852A3 Method for directed packaging of molecular substances in protein shells |
| 12/13/2001 | WO2001026682A3 Modified plant viruses and methods of use thereof |
| 12/13/2001 | WO2001020026A3 POLYMORPHISMS IN THE HUMAN hPXR GENE AND THEIR USE IN DIAGNOSTIC AND THERAPEUTIC APPLICATIONS |
| 12/13/2001 | WO2001011048A3 Therapeutic polypeptides and methods for using same |
| 12/13/2001 | WO2001011038A3 Medicament for the prevention and/or the treatment of ischemic heart and peripheral vascular diseases, tumour and wounds |
| 12/13/2001 | WO2000065076A3 Synthetic gene for expressing active retroviral protein in eukaryotes |
| 12/13/2001 | WO2000032773A9 Compositions and methods for increasing bone mineralization |
| 12/13/2001 | WO2000018903A9 Inducible genetic suppression of cellular excitability |
| 12/13/2001 | WO2000015845A9 T-type calcium channel |
| 12/13/2001 | US20010052136 Compositions and methods for producing and using homogenous neuronal cell transplants |
| 12/13/2001 | US20010051611 Supplying protein, antibodies, ribozymes |
| 12/13/2001 | US20010051610 Using transition metal compound promoter |
| 12/13/2001 | US20010051609 Administering Dna |
| 12/13/2001 | US20010051608 Drug delivery |
| 12/13/2001 | US20010051375 Highly efficient gene transfer into human repopulating stem cells by RD114 pseudotyped retroviral vector particles |
| 12/13/2001 | US20010051358 Nucleotide sequences coding preferential pollypeptides; for use in the treatment of nervous system, vision, kidney and liver disorders; wound healing agents; anticarcinogenic agents |
| 12/13/2001 | US20010051148 Pretreatment transplantation of organs; genetic engineered culture product |
| 12/13/2001 | DE10027777A1 Introducing substances into cells of sensory organs, useful for treating degenerative disorders of ear and eye, uses penetratin as transporter molecule |
| 12/13/2001 | DE10027170A1 Humanes PEM als Target für die Fertilitätskontrolle Human PEM as a target for fertility control |
| 12/13/2001 | DE10025609A1 Transfektionssystem Transfection |
| 12/13/2001 | CA2810249A1 Identification and use of human bone marrow-derived endothelial progenitor cell to improve myocardial function after ischemic injury |
| 12/13/2001 | CA2414076A1 Multivalent platform molecules comprising high molecular weight polyethylene oxide |
| 12/13/2001 | CA2412436A1 Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury |
| 12/13/2001 | CA2412377A1 B7-related nucleic acids and polypeptides and their uses for immunomodulation |
| 12/13/2001 | CA2412026A1 Immunostimulatory rna/dna hybrid molecules |
| 12/13/2001 | CA2411762A1 Method for obtaining characterised muscle-derived cell populations and uses |
| 12/13/2001 | CA2411596A1 Therapeutic agents - ii |